FORO DE I+D BIOMEDICA GLOBAL

1. FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE BIOSCIENCES AND BIOTECH GROWTH Carlos Martinez-A

2. Communicating biotech .... BioPlastic is plastic BioDiesel is diesel. Corn is corn Soya is soya Medicines are medicines

3. European Biotech Industry? Here? Here? Here? Here? Here? Here? Follow on Pre-seed Seed VC IPO Debt Or along the capital pipeline?

4. European Biotech Industry • Fragmentation  lack of critical mass: • Product markets • Financial markets • Regulatory frameworks • Centers of excellence and clusters • Business attitude • Political attitude • “10-year gap” • Lack of all forms of finance

5. European Biotech Industry Source: Critical I and EuropaBio

6. European Biotech Industry Source: Critical I and EuropaBio

7. … less products in development Lower R&D budgets in Europe, means… European Biotech Industry

8. La productividad de las biotech es superior a la de las farmacéuticas European Biotech Productivity Fuente: Ernst & Young, Beyond Borders (Biotech Report), Nov 2005

9. European Biotech Productivity Durante el 2005 las compañías de biotecnología han experimentado una rentabilidad superior a las Farmacéuticas y a los principales índices Fuente: Bloomberg, Abn Amro

10. European Biotech Productivity European Biotech Industry Valor de capitalización bursátil (miles de millones de dólares) Programas en fase clínica (Numero de programas) 958 … En su conjunto el valor de capitalización bursátil del sector es igual al valor bursátil de Pfizer y GSK …. con 8 veces el potencial de crecimiento 343,3 334,9 Fase II/III 110 Fase I Fase II/III Fase I World Biotech Sector Pfizer y Glaxosmithkline World Biotech Sector Pfizer y Glaxosmithkline Fuente: GS Global research 2003, SG Cowen Pipeline Plus March 2004, BB Biotech

11. European Biotech Industry Political risks VALUE R&D risks IP risks Financing risks Regulatory risks RISK Market risks TIME

12. Political support European Biotech Industry VALUE R&D risks Political risks IP risks Financing risks Regulatory risks RISK Market risks TIME

13. Ingenio 2010 The Spanish Government has presented the INGENIO 2010 program to stimulate R&D+i • Reach 2% of the GDP for R&D in 2010 and 1.5% in 2007 • Reach 55% private contribution in R&D investment in 2010 • Achieve the EU mean in the percentage of the GDP assigned for TIC, to go from 4.8% in 2004 to 7% in 2010 OBJECTIVES Budget ≈ 8.000 M€ • CENIT: public-private collaboration • CENIT projects • Fund of Capital Risk funds • “Torres Quevedo” Program • Increased the number of spin-offs by four folds • CONSOLIDER: increase critical mass and researcher excellence • Avanz@: convergence of the EU with the Information Society INSTRUMENTS

14. CSIC: over 60 years devoted to R&D 1907: Council for the Extension of Studies and Scientific Research Santiago Ramón y Cajal The Nobel Prize in Physiology or Medicine 1906 Severo Ochoa The Nobel Prize in Physiology or Medicine 1959

15. PAIS VASCO CANTABRIA • Organised: • Network of 116 Institutes (including 40 joint Centres with other Institutions) • 134 Associated Units ASTURIAS [1] [2] 2 GALICIA NAVARRA 3+[1] CATALUÑA [1] 13+[4]+(3) CASTILLA-LEON ARAGON 2+[3] 3+[3] MADRID BALEARES 33+[7]+(5) [1] C. VALENCIANA CASTILLA-LA MANCHA 3+[7] EXTREMADURA [1] 1+[1] MURCIA 1 ANDALUCIA 13+[7]+(1) ROMA 1 1 CSIC: over 60 years devoted to R&D • Performing: • Multidisciplinary Scientific and Technological Research • Scientific and Technical Assessments • Training of scientific and technical personnel • Management of infrastructures • Collaborating with: • Universities • Other public R&D Organisations • Industries • Enterprises, Professional Associations and Foundations • Regional Governments

16. NATIONAL RESEARCH PLAN OF R&D INDUSTRY 40,7% 18,% 15,% 16,% REGIONAL GOVERNMENTS EU OTHERS 7,9% TOTAL: 204 M€ HUMAN RESOURCES 2.400 Research Staff 4.000 Postgraduate students and Postdocs 4.000 Administrative and Technicians TOTAL : 10.400 Budget & Human Resources BUDGET TOTAL BUDGET: 530 M€ MEC 61,5 % 38,5 % External resources

17. CSIC Institutes in the Scientific Area of Biology and Biomedicine Andalusian Center of Developmental Biology. CABD, Sevilla Andalusian Center of Molecular Biology and Regenerative Medicine. CABIMER, Sevilla Center of Cardiovascular Research. CIC, Barcelona Center for Regenerative Medicine, CMR, Barcelona Center of Biological Research. CIB, Madrid National Center of Biotechnology. CNB, Madrid Institute of Molecular and Cellular Biology “Primo Yúfera”. IBMCP, Valencia Institute of Molecular and Cellular Biology of Cancer. IBMCC, Salamanca Institute of Molecular Biology of Barcelona. IBMB, Barcelona Laboratory of Plant Genetics-IBMB. Barcelona Center of Molecular Biology, CBM, Madrid Institute of Biology and Molecular Genetics. IBGM, Valladolid Institute of Biomedicine of Valencia. IBV, Valencia Institute of Plant Biology and Photosynthesis. IBVF, Sevilla Institute of Biomedical Research “Alberto Sols”. IIB, Madrid Institute of Biomedical Research of Barcelona. IIBB, Barcelona Institute of Biochemical Microbiology. IMB, Salamanca Institute of Neurobiology “Ramón y Cajal”. INRC, Salamanca Institute of Neurosciences of Alicante. INA, Alicante Institute of Parasitology and Biomedicine “López Neyra”. IPBLN, Granada Unit of Biophysics. UBF, Bilbao 21 Research Centers

18. RECURSOS ECONÓMICOS

19. KNOWLEDGE TRANSFER • EMPRESAS DE BASE TECNOLÓGICA

20. CSIC – Asia Collaboration CSIC’s Subscribed Agreements CHINA Chinese Academy of Sciences (CAS) National Natural Science Foundation (NSFC) Bottom-up approach JAPAN Japan Society for the Promotion of Science (JSPS) Republic of KOREA Korea Science and Engineering Foundation (KOSEF) Joint projects and exchange of researchers TAIWAN National Science Council (NSC) VIETNAM Vietnamese Academy of Science and Technology (VAST)

21. Thank you! Gracias!